The estimated Net Worth of R Douglas Norby is at least $11.6 Million dollars as of 9 May 2018. Mr. Norby owns over 9,000 units of Krystal Biotech Inc stock worth over $1,789,110 and over the last 21 years he sold KRYS stock worth over $9,775,318. In addition, he makes $61,500 as Lead Independent Director at Krystal Biotech Inc.
R has made over 17 trades of the Krystal Biotech Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 9,000 units of KRYS stock worth $93,780 on 9 May 2018.
The largest trade he's ever made was selling 45,442 units of Krystal Biotech Inc stock on 11 December 2015 worth over $8,529,918. On average, R trades about 7,094 units every 78 days since 2003. As of 9 May 2018 he still owns at least 9,000 units of Krystal Biotech Inc stock.
You can see the complete history of Mr. Norby stock trades at the bottom of the page.
R. Douglas Norby serves as Lead Independent Director of the Company. Mr. Norby is a director of SymBio Pharmaceuticals, Ltd., a Japanese pharmaceutical company listed on the Tokyo Exchange, and previously served as lead independent director on the board of directors of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), where he was a board member from September 1999 to September 2019. Mr. Norby has held positions of responsibility at many companies, including serving as Senior Vice President and Chief Financial Officer of Tessera, Inc., a provider of intellectual property for advanced semiconductor packaging; and as Senior Vice President and Chief Financial Officer of Zambeel, Inc., a data storage systems company. Mr. Norby has also served as Senior Vice President and Chief Financial Officer of Novalux, Inc., a manufacturer of lasers for optical networks; as Executive Vice President and Chief Financial Officer of LSI Logic Corporation, a semiconductor company which was acquired by Avago Technologies in 2013; as Senior Vice President and Chief Financial Officer of Mentor Graphics Corporation, a software company; and as President and Chief Operating Officer at Lucasfilm, Ltd., an entertainment company. His pharmaceutical experience includes serving as President of Pharmetrix Corporation, a drug delivery company, as Senior Vice President and Chief Financial Officer of Syntex Corporation, a pharmaceutical company, which was later acquired by Roche Holding Ltd. Mr. Norby received a bachelor’s degree in Economics from Harvard University and an MBA from Harvard Business School.
As the Lead Independent Director of Krystal Biotech Inc, the total compensation of R Norby at Krystal Biotech Inc is $61,500. There are 8 executives at Krystal Biotech Inc getting paid more, with Krish S. Krishnan M.B.A., M.S. having the highest compensation of $1,008,932.
R's mailing address filed with the SEC is 20400 STEVENS CREEK BOULEVARD, SUITE 370, , CUPERTINO, CA, 95014.
Over the last 7 years, insiders at Krystal Biotech Inc have traded over $166,816,526 worth of Krystal Biotech Inc stock and bought 536,800 units worth $5,949,380 . The most active insiders traders include Daniel Janney, Dino A Rossi, and Krish S Krishnan. On average, Krystal Biotech Inc executives and independent directors trade stock every 40 days with the average trade being worth of $8,043,043. The most recent stock trade was executed by Suma Krishnan on 11 June 2024, trading 50,000 units of KRYS stock currently worth $8,788,000.
krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)
Krystal Biotech Inc executives and other stock owners filed with the SEC include: